Yanlei Zhang

机构：Chinese Academy of Medical Sciences & Peking Union Medical College, Shanghai CASB Biotechnology (China), Institute of Hematology & Blood Diseases Hospital, Shanghai Cell Therapy Research Institute, China University of Petroleum, East China · ORCID：0000-0002-7658-7691

发表论文 102 篇 · 总被引 2594 次 · h-index 23

代表论文

Anti-BCMA/GPRC5D bispecific CAR T cells in patients with relapsed or refractory multiple myeloma: a single-arm, single-centre, phase 1 trial (2024 · The Lancet Haematology · 被引 60)
Anti-GPRC5D CAR T-cell therapy as a salvage treatment in patients with progressive multiple myeloma after anti-BCMA CAR T-cell therapy: a single-centre, single-arm, phase 2 trial (2025 · The Lancet Haematology · 被引 24)
Long-term follow-up of BCMA CAR-T cell therapy in patients with relapsed/refractory multiple myeloma (2025 · Journal for ImmunoTherapy of Cancer · 被引 17)
Autologous CD7 CAR-T cells generated without T cell pre-selection in pediatric patients with relapsed/refractory T-ALL: A phase I trial (2024 · Molecular Therapy · 被引 13)
Donor-derived CD7 CAR T cells for pediatric and adult relapsed/refractory T-ALL/LBL: a phase 2 trial (2025 · Blood · 被引 8)
Phase II Study of BCMA Chimeric Antigen Receptor T-Cell Therapy in Patients With Newly Diagnosed Multiple Myeloma Ineligible for or Not Proceeding to Autologous Stem-Cell Transplantation (CAREMM-001) (2026 · Journal of Clinical Oncology · 被引 4)